Literature DB >> 15477877

Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.

H Kakinuma1, N Tsuchiya, T Habuchi, C Ohyama, S Matsuura, L Wang, A Nakamura, T Kato.   

Abstract

Polymorphism of the steroid hormone-related genes might affect life-long androgen exposure, thus altering a risk of prostate cancer incidence. To evaluate the effect of the polymorphisms of CYP17 and SRD5A2 on serum steroid hormone levels, the 164 male Japanese cohort were tested for serum hormone levels and the genotype of the polymorphisms of CYP17 (T-C base substitution in the promoter region) and SRD5A2 (V89L). The linear trends across the CYP17 genotypes in serum-free testosterone and androstenedione levels were found, suggesting the importance of the polymorphism of CYP17 in determining the circulating androgen levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477877     DOI: 10.1038/sj.pcan.4500753

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  5 in total

1.  CYP17 polymorphisms and prostate cancer outcomes.

Authors:  Jonathan L Wright; Erika M Kwon; Daniel W Lin; Suzanne Kolb; Joseph S Koopmeiners; Ziding Feng; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-07-01       Impact factor: 4.104

2.  Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Authors:  Akinobu Hamada; Romano Danesi; Douglas K Price; Tristan Sissung; Cindy Chau; David Venzon; Alex Sparreboom; William L Dahut; William D Figg
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

3.  Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.

Authors:  Takeshi Yamada; Masashi Nakayama; Tomohito Shimizu; Shinpei Nonen; Yasutomo Nakai; Kazuo Nishimura; Yasushi Fujio; Akihiko Okuyama; Junichi Azuma; Norio Nonomura
Journal:  Int J Clin Oncol       Date:  2012-06-21       Impact factor: 3.402

4.  Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.

Authors:  Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 5.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.